Evaluation of Fixed-Dose Daptomycin in Obese Patients With Bloodstream Infections Caused by Staphylococcus aureus

Abstract

Get full access to this article

View all access options for this article.

References

Falcone

Russo

Venditti

Novelli

Pai

. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57:1568-1576. doi:10.1093/cid/cit582

Flegal

Kruszon-Moran

Carroll

Fryar

Ogden

. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284-2291. doi:10.1001/jama.2016.6458

Pai

Norenberg

Anderson

, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007;51:2741-2747. doi:10.1128/AAC.00059-07

Butterfield-Cowper

Lodise

Jr Pai

. A fixed versus weight-based dosing strategy of daptomycin may improve safety in obese adults. Pharmacotherapy. 2018;38:981-985. doi:10.1002/phar.2157

Martin

Harris

Brooks

Main

Mertz

. Management and outcomes in patients with Staphylococcus aureus bacteremia after implementation of mandatory infectious diseases consult: a before/after study. BMC Infect Dis. 2015;15:568. doi:10.1186/s12879-015-1296-y